Press Release | Excellergy Inc.

Novartis Acquisition

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development…

Excellergy EditorialMarch 26, 2026

EXL 111 bound to IGE 00405ultra

Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control and Announces First Subjects Dosed in Phase 1 DISARM Trial

Exl-111 is an investigational allergic Effector Cell Response Inhibitor (ECRI) targeting the IgE axis and…

Excellergy EditorialFebruary 27, 2026

Excellergy1

Excellergy Debuts with $70 Million Series A Financing to Advance First-in-Class Portfolio of Trifunctional Effector Cell Response Inhibitors (ECRIs) for Complete Allergic Control

Redefining Allergy Treatment with New Class of Trifunctional ECRIs designed to deliver powerful efficacy, rapid…

Excellergy EditorialOctober 13, 2025